Latest News
Thursday October 16, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that a special meeting of shareholders to vote on the proposed acquisition of Barr Pharmaceuticals, Inc. by Teva Pharmaceutical Industries Ltd. has been set for November 21, 2008. The meeting will be he...
Thursday October 16, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that a special meeting of shareholders to vote on the proposed acquisition of Barr Pharmaceuticals, Inc. by Teva Pharmaceutical Industries Ltd. has been set for November 21, 2008. The meeting will be he...
Thursday October 16, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that a special meeting of shareholders to vote on the proposed acquisition of Barr Pharmaceuticals, Inc. by Teva Pharmaceutical Industries Ltd. has been set for November 21, 2008. The meeting will be he...
Thursday October 16, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that a special meeting of shareholders to vote on the proposed acquisition of Barr Pharmaceuticals, Inc. by Teva Pharmaceutical Industries Ltd. has been set for November 21, 2008. The meeting will be he...
Thursday October 16, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that a special meeting of shareholders to vote on the proposed acquisition of Barr Pharmaceuticals, Inc. by Teva Pharmaceutical Industries Ltd. has been set for November 21, 2008. The meeting will be he...
Thursday October 16, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that a special meeting of shareholders to vote on the proposed acquisition of Barr Pharmaceuticals, Inc. by Teva Pharmaceutical Industries Ltd. has been set for November 21, 2008. The meeting will be he...
Thursday October 16, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that a special meeting of shareholders to vote on the proposed acquisition of Barr Pharmaceuticals, Inc. by Teva Pharmaceutical Industries Ltd. has been set for November 21, 2008. The meeting will be he...
Thursday October 16, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that a special meeting of shareholders to vote on the proposed acquisition of Barr Pharmaceuticals, Inc. by Teva Pharmaceutical Industries Ltd. has been set for November 21, 2008. The meeting will be he...
Tuesday October 7, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Oct. 7 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that the Company will host a Conference Call at 8:30 AM Eastern time on Thursday, November 6 to discuss earnings results for the third quarter of calendar 2008, ended September 30, 2008. The number to c...
Thursday September 25, 2008 — Duramed Pharmaceuticals, Inc.
MONTVALE, N.J., Sept. 25 /PRNewswire/ -- While the majority of adults aged 50 to 70 agree that decreased frequency, physical ability to have or desire for sex is expected with age, a recent survey indicates that women were less prepared than men for the physical changes that are often associated ...
Wednesday September 17, 2008 — Barr Pharmaceuticals, Inc.
MONTVALE, N.J., Sept. 16 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc., received final approval from the U.S. Food Drug Administration (FDA) to manufacture and market a generic version of Ortho McNeil Janssen's Razadyne(R) ER (...
Thursday September 4, 2008 — Teva Pharmaceutical Industries Ltd.; Barr Pharmaceuticals, Inc.
JERUSALEM and MONTVALE, N.J., Sept. 3 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that, as expected, each party has received a request for additional information (commonly referred to as a "second request") from the U.S. Federal T...
Thursday September 4, 2008 — Teva Pharmaceutical Industries Ltd.; Barr Pharmaceuticals, Inc.
JERUSALEM and MONTVALE, N.J., Sept. 3 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that, as expected, each party has received a request for additional information (commonly referred to as a "second request") from the U.S. Federal T...
Thursday September 4, 2008 — Teva Pharmaceutical Industries Ltd.; Barr Pharmaceuticals, Inc.
JERUSALEM and MONTVALE, N.J., Sept. 3 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that, as expected, each party has received a request for additional information (commonly referred to as a "second request") from the U.S. Federal T...
Thursday September 4, 2008 — Teva Pharmaceutical Industries Ltd.; Barr Pharmaceuticals, Inc.
JERUSALEM and MONTVALE, N.J., Sept. 3 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that, as expected, each party has received a request for additional information (commonly referred to as a "second request") from the U.S. Federal T...
Thursday September 4, 2008 — Teva Pharmaceutical Industries Ltd.; Barr Pharmaceuticals, Inc.
JERUSALEM and MONTVALE, N.J., Sept. 3 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that, as expected, each party has received a request for additional information (commonly referred to as a "second request") from the U.S. Federal T...
Thursday September 4, 2008 — Teva Pharmaceutical Industries Ltd.; Barr Pharmaceuticals, Inc.
JERUSALEM and MONTVALE, N.J., Sept. 3 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that, as expected, each party has received a request for additional information (commonly referred to as a "second request") from the U.S. Federal T...
Thursday September 4, 2008 — Teva Pharmaceutical Industries Ltd.; Barr Pharmaceuticals, Inc.
JERUSALEM and MONTVALE, N.J., Sept. 3 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that, as expected, each party has received a request for additional information (commonly referred to as a "second request") from the U.S. Federal T...
Thursday September 4, 2008 — Teva Pharmaceutical Industries Ltd.; Barr Pharmaceuticals, Inc.
JERUSALEM and MONTVALE, N.J., Sept. 3 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that, as expected, each party has received a request for additional information (commonly referred to as a "second request") from the U.S. Federal T...
Thursday September 4, 2008 — Teva Pharmaceutical Industries Ltd.; Barr Pharmaceuticals, Inc.
JERUSALEM and MONTVALE, N.J., Sept. 3 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that, as expected, each party has received a request for additional information (commonly referred to as a "second request") from the U.S. Federal T...
Thursday September 4, 2008 — Teva Pharmaceutical Industries Ltd.; Barr Pharmaceuticals, Inc.
JERUSALEM and MONTVALE, N.J., Sept. 3 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that, as expected, each party has received a request for additional information (commonly referred to as a "second request") from the U.S. Federal T...
Thursday September 4, 2008 — Teva Pharmaceutical Industries Ltd.; Barr Pharmaceuticals, Inc.
JERUSALEM and MONTVALE, N.J., Sept. 3 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that, as expected, each party has received a request for additional information (commonly referred to as a "second request") from the U.S. Federal T...
Thursday September 4, 2008 — Teva Pharmaceutical Industries Ltd.; Barr Pharmaceuticals, Inc.
JERUSALEM and MONTVALE, N.J., Sept. 3 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that, as expected, each party has received a request for additional information (commonly referred to as a "second request") from the U.S. Federal T...
Thursday September 4, 2008 — Teva Pharmaceutical Industries Ltd.; Barr Pharmaceuticals, Inc.
JERUSALEM and MONTVALE, N.J., Sept. 3 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that, as expected, each party has received a request for additional information (commonly referred to as a "second request") from the U.S. Federal T...
Thursday September 4, 2008 — Teva Pharmaceutical Industries Ltd.; Barr Pharmaceuticals, Inc.
JERUSALEM and MONTVALE, N.J., Sept. 3 /PRNewswire-FirstCall/ -- Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. announced today that, as expected, each party has received a request for additional information (commonly referred to as a "second request") from the U.S. Federal T...